International Law Office
Trade Negotiators Seek Comment on Elimination of Pharmaceutical Import Duties
April 23, 2010
Over 9,000 pharmaceutical and chemical intermediates enjoy duty free treatment under the customs regime of the United States and other countries that participate in the World Trade Organization Pharmaceutical Agreement. The Office of the U.S. Trade Representative is seeking public comment on the possible expansion of the list of products subject to this reciprocal duty free treatment (comments were due by April 9, 2010).
This Sidley Update was republished by ILO in its Trade & Customs Newsletter.
Capabilities
Suggested News & Insights
UK Overhauls Trade Remedies System: Key Takeaways for Global BusinessesDecember 18, 2025Sidley Advises Coinbase Capital Markets on the Launch of Its Stock Trading Capability for U.S. Coinbase UsersDecember 17, 2025Sidley Ranked in Chambers Asia-Pacific 2026December 11, 2025Sidley Elects Partnership Class of 29 and Counsel Class of 15 Across Europe and U.S.December 11, 2025Clear and Present Danger: How DOJ Trade-Fraud and Anti-Corruption Priorities Show Trade & Customs Risks Are Here to StayDecember 9, 2025U.S. and UK Announce Agreement Exempting UK-Origin Pharmaceuticals from TariffsDecember 5, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory